Source:http://linkedlifedata.com/resource/pubmed/id/16501834
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2006-2-27
|
| pubmed:abstractText |
We conducted clinicopathologic and immunohistochemical analyses of the prevalence of Epstein-Barr virus (EBV) among 24 patients with malignant lymphoma complicating systemic rheumatic diseases. (SRD) These 24 patients included 17 with rheumatoid arthritis (RA), 3 with systemic lupus erythematosus (SLE), 2 with systemic sclerosis (SS), and 2 with dermatomyositis (DM). There were 2 men and 22 women ranging in age from 30 to 86 years (mean: 64 years). The interval between the onset of rheumatic disease and that of malignant lymphomas ranged from 3 months to 35 years (mean: 142 months). The use of immunosuppressive drugs before the onset of malignant lymphoma was recorded in 15 patients. Among them, 5 patients received methotrexate (MTX) therapy. Malignant lymphomas were found at extranodal sites in 9 patients, and the disease was in the advanced stage in 17 patients. Histologic and immunohistochemical studies demonstrated that 18 cases (75%) were B-cell lymphoma (RA=12, SLE=2, SS=2, DM=2), 3 (12.5%) were peripheral T-cell lymphoma (RA=3), and 3 (12.5%) were classical Hodgkin lymphoma (RA=2, SLE=1). As in previous reports, there was an increased frequency of diffuse large B-cell lymphoma (50%) in the present series. Moreover, a majority of the diffuse large B-cell lymphomas exhibited activated B-cell phenotype. EBV-encoded small RNAs (Epstein-Barr early region [EBER]-) and/or LMP-1+tumor cells were identified in only 3 cases of classical Hodgkin lymphomas. Our findings suggested EBV-associated lymphoma comprised only a small fraction of all non-Hodgkin's lymphomas in the general SRD patient population.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
1066-8969
|
| pubmed:author |
pubmed-author:HiguchiKeikoK,
pubmed-author:HirabayashiKaoruK,
pubmed-author:IgarishiSeijiS,
pubmed-author:ItohHideakiH,
pubmed-author:KojimaMasaruM,
pubmed-author:MasawaNobuhideN,
pubmed-author:MatsumotoMorioM,
pubmed-author:MurayamaKayokoK,
pubmed-author:NakamuraShigeoS,
pubmed-author:SarukiNobuhiroN,
pubmed-author:ShimizuKazuhikoK,
pubmed-author:TamakiYoshioY
|
| pubmed:issnType |
Print
|
| pubmed:volume |
14
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
43-8
|
| pubmed:meshHeading |
pubmed-meshheading:16501834-Adult,
pubmed-meshheading:16501834-Aged,
pubmed-meshheading:16501834-Aged, 80 and over,
pubmed-meshheading:16501834-Antigens, CD20,
pubmed-meshheading:16501834-Arthritis, Rheumatoid,
pubmed-meshheading:16501834-Dermatomyositis,
pubmed-meshheading:16501834-Epstein-Barr Virus Infections,
pubmed-meshheading:16501834-Female,
pubmed-meshheading:16501834-Herpesvirus 4, Human,
pubmed-meshheading:16501834-Hodgkin Disease,
pubmed-meshheading:16501834-Humans,
pubmed-meshheading:16501834-Immunohistochemistry,
pubmed-meshheading:16501834-Japan,
pubmed-meshheading:16501834-Lupus Erythematosus, Systemic,
pubmed-meshheading:16501834-Lymphoma,
pubmed-meshheading:16501834-Lymphoma, B-Cell,
pubmed-meshheading:16501834-Lymphoma, T-Cell,
pubmed-meshheading:16501834-Male,
pubmed-meshheading:16501834-Middle Aged,
pubmed-meshheading:16501834-RNA, Viral,
pubmed-meshheading:16501834-Rheumatic Diseases,
pubmed-meshheading:16501834-Scleroderma, Systemic
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Malignant lymphoma in patients with systemic rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and dermatomyositis): a clinicopathologic study of 24 Japanese cases.
|
| pubmed:affiliation |
Department of Pathology and Clinical Laboratories, Gunma Cancer Center Hospital, Ohta, Dokkyo University School of Medicine, Mibu, Japan.
|
| pubmed:publicationType |
Journal Article
|